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The aim of the study was to investigate the dose-dependent in vivo effect of alpha-melanocyte
stimulating hormone (-MSH) in a rat model of inflammatory bowel disease induced by 2,4,6-tri-
nitrobenzene sulphonic acid (TNBS). Laboratory animals (male Wistar rats weighing 200–250 g)
were given 3 doses of -MSH (0.5 mg/kg, 1 mg/kg, 2 mg/kg) intraperitoneally 1 hour prior to
inducing colitis with a TNBS enema. Control animals received saline solution i.p. Rats were
sacrificed after 72 hours and the area of mucosal lesions, involving the distal 10 cm of colon,
was determined in mm2 by means of image analysis software. -MSH structure was analyzed
by means of NMR spectroscopy. The area of colonic damage was significantly reduced following
pretreatment with a single dose of 1 mg/kg -MSH, as compared to control animals (p = 0.0147).
Higher and lower doses had no significant effects. A single dose of 1 mg/kg -MSH provided
strong, statistically significant and pharmacologically relevant cytoprotection. The results point
to -MSH effectiveness in controlling inflammation and imply that further in vitro and in vivo
experiments should be carried out to judge the importance and relevance of -MSH in the con-
trol of inflammatory bowel disease. NMR data support a hairpin loop conformation of -MSH
in water solution, which includes conserved message sequence.
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INTRODUCTION
Inflammatory bowel disease results from a deregulated
immune response to yet undefined stimulus/stimuli that
lead to mucosal inflammation characterized by rectal
bleeding, diarrhoea and abdominal pain.1–3
Thus far, there is no unique effective treatment for
the disorder. Therapy is directed toward controlling in-
flammation (5-aminosalicylic acid, antibiotics, and some
diets), the immune response (azathioprin, cyclosporine,
metotrexate, 6-mercaptopurine, and Infliximab) or both
(corticosteroids).4 The search for more effective agents
continues.3,5
One of the possible therapeutic agents is alpha-me-
lanocyte stimulating hormone, i.e., alpha-melanotropin
(-MSH), a 13-amino acid peptide derivate of cortico-
tropin (ACTH). There is a growing body of evidence
that endogenous -MSH is part of the host reaction to
infectious and inflammatory stimuli in humans.6–10 Ob-
servations indicate that there is generally a compensa-
tory increase in neuropeptide in the presence of inflamma-
tion.7,11 It likewise reduces synthesis of proinflammatory
cytokines in human disease,8,12,13 suggesting that when-
ever the increase in endogenous -MSH is not adequate,
the disease process is more severe. In such situations, treat-
ment with -MSH could be beneficial and preclinical stud-
ies have identified potential therapeutic targets, includ-
ing allergic inflammation, uveoretinitis, brain inflamma-
tion, rheumatoid arthritis, septic shock and asthma.7,11–16
Furthermore, -MSH and its receptor have been isolated
from the gut, implicating its contribution to local inflam-
matory and anti-inflammatory processes.11,13 Some data
confirming the beneficial effect of -MSH on lesions in
the digestive system already exist.13,17–20
The present study was designed to evaluate the dose-
-dependent protective effect of -MSH in a classical rat
model of inflammatory bowel disease and to obtain ad-
ditional information on the structure and conformation of
the -MSH molecule.
EXPERIMENTAL
TNBS Colitis
Experimental animals were male Wistar rats bred at the
School of Medicine, Zagreb, Croatia, weighing 200–250 g,
randomized in five experimental and one control group (six
rats per group). The animals were kept in a room with con-
stant temperature (22  1 °C) and a dark-light cycle (12 h/
12 h), housed in cages, maximum 6 rats per cage. They were
fed standard laboratory rodent pellets and given water ad li-
bitum. Animals were food-fastened with free access to wa-
ter 12 h prior to inducing colitis and sacrificing.
The tested substance -MSH (SYSMEHFRWGKPV,
>97 % purity; CBI, USA), was administered in 3 progres-
sive doses of 0.5 mg/kg (A), 1 mg/kg (B) and 2 mg/kg (C)
dissolved in 0.9 % NaCl up to the volume of 1 mL. This
volume was given intraperitoneally (i.p.) 1 h prior to the in-
duction of colitis. Pure saline solution was used in the con-
trol group to correct the influence of volume load.
After light ether anesthesia, colitis was induced by ap-
plying 1 mL of a solution containing 30 mg of 2,4,6-trini-
trobenzene sulphonic acid (TNBS) (Sigma, USA) dissolved
in 40 % ethanol, via rectal catheter. Rats were sacrificed 72
hours after the TNBS installation, when maximal extent of
colonic damage was expected.21,22 The last 10 cm of the
colon was examined. Lesions (hemorrhagic and necrotic ar-
eas) were determined in mm2 by means of image analysis
software (GIMP and ImageJ programs).
Statistical analysis and comparison of control and treat-
ed groups was performed with ANOVA and the Tukey HSD
test.
NMR Measurements
The structure and conformation of -MSH were analyzed
by one- and two-dimensional homo- and hetero-nuclear 1H
and 13C NMR spectroscopy. The spectra of -MSH were
recorded with a Bruker AV-600 spectrometer, operating
at 600.133 MHz and 150.917 MHz for the 1H and 13C
nuclei, respectively. The concentration of samples was ca.
2–5 mmol dm–3. Samples were dissolved in water with the ra-
tio D2O:H2O = 1:10. Measurements were performed at 30 °C
(303 K) in 5 mm NMR tubes at pH = 7.0 in 50 mmol dm–3
sodium phosphate buffer. Chemical shifts, in ppm, were re-
ferred to the water signal.
In 1H NMR and 13C NMR spectra the FID resolution
was 0.29 Hz and 0.44 Hz per point, respectively. The mea-
suring techniques used were: standard 1H, COSY, TOCSY,
NOESY and ROESY. All spectra were recorded in the phase-
-sensitive mode. In COSY and NOESY measurements, pro-
ton decoupling was performed by Waltz-16 modulation.
Two-dimensional measurements were done using pulsed
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TABLE I. The 1H chemical shifts (/ppm)(a) of residues in -MSH
Proton: NH CH CH Other H
Residue /ppm
Ser1 (S) 8.25 4.60 3.9
3.95
Tyr2 (Y) 8.25 4.60 3.00
3.10
7.15
6.85
Ser3 (S) 8.22 4.60 3.72
3.95
Met4 (M) 8.26 4.50 2.10
2.05
2.61; 2.63
2.10
Glu5 (E) 8.11 4.45 2.22
2.05
2.30
His6 (H) 8.56 3.22 3.41 7.11
8.65
Phe7 (F) 8.30 4.65 3.20 7.20
7.28
Arg8 (R) 8.25 4.40 1.83
1.70
1.45; 3.05
3.08; 7.05
Trp9 (W) 8.25 4.60 3.11
3.23
7.25; 10.63
7.65; 7.45
Gly10 (G) 8.15 4.03 4.05
Lys11 (K) 8.18 4.31 1.62
1.70
1.47; 1.43
1.75
Pro12 (P) 4.50 2.00
2.18
2.00; 2.12
3.58; 3.55
Val13 (V) 8.05 4.22 2.15 0.90; 0.92
aMeasured in water, ratio D2O : H2O = 1:10.
field gradient mode (z-gradient). The COSY spectrum was
recorded with 2048 points in F2 dimension and 512 incre-
ments in F1 dimension. The latter was subsequently zero-
filled to 1024 points. Every increment was obtained by 2
scans with spectral width 6127.45 Hz. The FID resolution
was 2.99 Hz/point and 11.96 Hz/point in F2 and F1 dimen-
sions, respectively. NOESY spectra were measured with mix-
ing times 0.2–1.0 s and 8 scans per each increment. ROESY
spectra were recorded with ROE mixing time 0.15–0.5 s.
The spectral width in NOESY and ROESY was 6127.45 Hz.
Numbers of points used were 2048 in F2 dimension (2.99
Hz/point) and 512 in F1 dimension, subsequently zero-filled
to 1024 points and in F2 (11.96 Hz/point). TOCSY spectra
were collected with a mixing time 60–80 ms using MLEV-
-17 pulses for spin-locking.
Sequential resonance assignments were performed on
the basis of TOCSY and NOESY spectral data. Backbone
assignment were completed from NOE connectivities, while
side-chain assignments from TOCSY connectivities. The 1H
chemical shift assignment is presented in Table I.
RESULTS AND DISCUSSION
Areas of hemorrhagic and necrotic damage were analyz-
ed separately and together (as total lesions); only results
for the total area of lesions are presented, since no major
differences between groups were observed in dependence
on the type of lesions. Severe colitis following intraco-
lonic administration of TNBS in ethanol was found in all
control untreated animals, as compared to normal rat co-
lonic mucosa. No changes in the microscopic damage
score between different groups were noted, only the total
area of lesions assessed in mm2 differed (Table II).
Depending on the type of pretreatment, different le-
vels of colonic damage were observed on the third day
after inducing colitis. ANOVA and subsequent post hoc
analysis with the Tukey HSD test show that TNBS-in-
duced mucosal damage was significantly reduced only in
the group pretreated with a 1 mg/kg dose -MSH (Table
II, Figure 1). The results of the measurements implicate
a dose-related modulatory effect of -MSH on the co-
lonic mucosal damage: protective effect arises when in-
creasing the dose from 0.5 mg/kg, peaks at 1 mg/kg, and
weakens with further dose increase to 2 mg/kg (Figure 1
and Table II).
The experimental model of TNBS colitis is a sim-
ple, inexpensive and popular animal model of the human
inflammatory bowel disease5,23 owing to its high repro-
ducibility (> 90 %), and dose-dependent tissue lesions.5
This robust model is suitable for the screening of cyto-
protective agents and drugs.5 Measuring the area of co-
lonic lesions is an exact and precise way to determine
the extent of colonic damage and it is more reliable than
semi-quantitative methods using macroscopical scoring
systems.21,22,24
The purity of -MSH was analyzed by Konjevoda et
al.25 to exclude the possibility of cytoprotective effects
of the substance being due to possible impurities. In the
central region of -MSH, a NOE between His6 and Phe7
and a strong NOE between Phe7 and Arg8 were observ-
ed (Table I). These NOEs support a turn conformation
consisting of His6, Phe7 and Arg8. Detection of NOE
between Glu5 and Trp9 supports the hairpin loop com-
prising residues Glu5-Trp9. NMR data are in agreement
with previous conclusions that -MSH forms a hairpin
loop conformation that includes conserved message se-
quence. Our NMR analyses confirm that -MSH region
from His6 to Trp9 (HFRW, Table I) constitutes an impor-
tant part of the molecule, responsible for the melanocortin
receptor binding and receptor subtype selectivity.14,26–28
The melanocortin receptor family consists of five sub-
types of melanocortin receptors (MC1R-MC5R).14,26,28
The ACTH melanocortin receptor (MC2R) requires for
ligand binding not only the conserved HFRW sequence
of -MSH but also a highly basic motif present solely in
the ACTH molecule.26 Other melanocortin receptor sub-
types are receptors for melanocyte-stimulating hormo-
nes.14,26,28
Mechanisms of -MSH protection in the colon are
not fully understood. TNBS exhibits hapten-like behav-
ior and induces an immune response5,21,23 with inflam-
mation that is characterized by neutrophil infiltration, in-
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TABLE II. Colonic damage (area of lesions / mm2) in the control
group and groups treated with progressive doses of -MSH prior
to inducing TNBS colitis (6 rats per group)
Pretreatment Mean Mini-
mum
Maxi-
mum
S.D.
Control (0.9 % NaCl) 754.7 356.0 1414.7 408.7
-MSH 0.5 mg/kg 368.9 176.0 578.0 179.4
-MSH 1 mg/kg 225.8 16.1 366.5 148.4
-MSH 2 mg/kg 336.4 34.0 672.5 270.8
ANOVA: F = 4.32, p = 0.0166, Tukey HSD test: p = 0.0147 control
vs. -MSH 1 mg/kg
± Std. Dev.
± Std. Err.
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Figure 1. Area of colonic lesions 72 h after inducing TNBS colitis
in rats pretreated with 3 progressive doses of -MSH: 0.5 mg/kg
(A), 1 mg/kg (B) and 2 mg/kg (C).
volvement of prostaglandins, leukotriens, tromboxane,
platelet activating factor, tumor necrosis factor-, inter-
leukin-1 cytokines, and the presence of Th1 lymphocyte
subpopulation followed by B-cell response (and inter-
leukin-2 activation in chronic disease model).5,21–23,29
According to the results of different in vitro studies, -
MSH could modulate many of these features.6,8–10,12 In
experiments concerning the gut, treatment with -MSH
influences the release of tumor necrosis factor-, nitric
oxide and interleukin-6 from bowel tissue,13,17 and there
is indirect evidence suggesting that prostaglandins partici-
pate in the salutary effect on colonic mucosa.18,19 How-
ever, it is likely that many more molecules involved in
the colonic inflammation are affected by -MSH, as a
consequence of reduced translocation of the nuclear fac-
tor kappa-B to the nucleus following peptide binding to
melanocortin receptor MC1R.11,14,30 Therefore, anti-in-
flammatory and immunomodulatory effects of -MSH
are broad, which makes it attractive for potential treat-
ment of inflammatory bowel disease at this point, when
no etiologic factors or specific mediators of the disease
have been recognized.
Our data identified the dose of 1 mg/kg of -MSH
to be effective in the rat model of inflammatory bowel
disease. The same dose was found optimal in studies of
gastric cytoprotection.20,31 However, lower and higher
doses were not effective in our study. The dose/effect
curve has a U-shape (Figure 1). Other neuropeptides ex-
hibit a similar dose-related effect. This can be explained
by additive effects of the peptide itself and its metabo-
lites in different concentrations, or by different receptor
affinities.10,32 On the other hand, a hypothetical auto-re-
gulatory mechanism has been suggested that would pro-
tect the host from excessive effects of the endogenously
produced or administered -MSH.7 Therefore, it seems
essential to apply a proper dose in order to achieve opti-
mal protective effects.
During the i.p. administration of -MSH no signs of
acute toxicity in rats were observed. Even higher doses
of -MSH were applied with no signs of toxicity.7 This
peptide is not accumulated in the body, which reduces
the probability of tolerance and toxicity and allows a
good control of pharmacological effects.11 Another ad-
vantage is that -MSH does not affect production of in-
flammatory mediators in resting conditions, nor does it
reduce microbial killing activity of the neutrophils, as
currently used anti-inflammatory drugs, in particular
corticosteroids do.11,33 All these features are in favor of
further investigations concerning -MSH as a potential
agent for the treatment of inflammatory bowel disease.
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Alfa-hormon koji stimulira melanocite smanjuje o{te}enje sluznice debeloga crijeva
u {takorskome modelu upalne bolesti crijeva
Du{ka Tje{i}-Drinkovi}, Dorian Tje{i}-Drinkovi}, Nikola [tambuk, Pa{ko Konjevoda,
Ana Votava-Rai}, Marijana Vinkovi} i Dra`en Viki}-Topi}
Svrha istra`ivanja bila je kvantifikacija in vivo u~inaka alfa-hormona koji stimulira melanocite (-MSH)
na {takorskome modelu upalne bolesti crijeva inducirane s 2,4,6-trinitrosulfonbenzenskom kiselinom (TNBS).
Laboratorijskim `ivotinjama (mu`jaci Wistar soja {takora tjelesne mase 200–250 g) dane su tri doze -MSH
(0.5 mg/kg, 1 mg/kg i 2 mg/kg) intraperitonealno 1 sat prije indukcije kolitisa s TNBS klizmom. Kontrolne su
`ivotinje primile fiziolo{ku otopinu intraperitonealno. Nakon 72 sata {takori su `rtvovani, te je pomo}u pro-
grama za analizu slike procjenjena povr{ina mukoznih lezija (mm2) unutar 10 distalnih centimetara kolona.
Struktura -MSH je analizirana uporabom NMR spektroskopije. Povr{ina o{te}enoga debeloga crijeva statisti-
~ki je zna~ajno smanjena kod pretretmana s jednom dozom 1 mg/kg -MSH, u odnosu na kontrolne `ivotinje
(p = 0.0147). Vi{e i ni`e doze nisu imale zna~ajne u~inke. Pojedina~na doza od 1 mg/kg -MSH uzrokovala je
statisti~ki zna~ajnu i farmakolo{ki relevantnu citoprotekciju. Rezultati ukazuju na u~inkovitost -MSH peptida
u kontroliranju upale i upu}uju na uporabu daljnjih in vitro i in vivo istra`ivanja kako bi se procijenio zna~aj i
u~inkovitost -MSH u kontroli upalne bolesti crijeva. NMR mjerenja u vodenoj otopini podupiru pretpostavku
o konformaciji -MSH i njegove konzervirane sekvencije u obliku ukosnice.
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